Metronomic cyclophosphamide with bevacizumab provides disease stabilization in patients with advanced uterine cancer

• We present two cases of advanced uterine cancer that were treated with the combination of metronomic cyclophosphamide and bevacizumab.
• Targeting angiogenesis can provide disease control in patients with advanced uterine cancer.
• Randomized controlled trials comparing metronomic and conventional regimens in advanced uterine cancer are required.